

**Amendments to the Claims**

The following listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

Claim 1 (previously presented) Monoclonal antibody directed against the protein of SEQ ID NO:1 and capable of inducing apoptosis in various types of tumor cells, wherein the antibody recognizes an epitope between amino acids 1 and 144 of SEQ ID NO:1.

Claim 2 (canceled)

Claim 3 (previously presented) Monoclonal antibody according to claim 1, capable of recognizing an epitope between amino acids 1 to 72 of SEQ ID NO:1.

Claim 4 (previously presented) The antibody Mab 1F1, secreted by the hybridoma line G3BP 1F1 1D1 deposited on 9 June 1998 at the C.N.C.M. under the number I-2038.

Claim 5 (canceled)

Claim 6 (canceled)

Claim 7 (previously presented) Pharmaceutical composition comprising a therapeutically effective quantity of the monoclonal antibodies according to claim 1, the said quantity being therapeutically effective for inducing apoptosis in tumor cells.

Claim 8 (previously presented) Hybridoma line capable of secreting monoclonal antibodies according to claim 1.

Claim 9 (original) Hybridoma line G3BP 1F1 1D1 deposited on 9 June 1998 at the C.N.C.M. under the deposit number I-2038.

Claim 10 (withdrawn) Method of producing monoclonal antibodies capable of inducing apoptosis in various tumor lines, characterized in that it comprises (1) the fusion of

spleen cells from an animal immunized with the aid of the G3BP protein or of a fragment comprising at least a portion of the N-terminal domain (aa 1-144), with myelomatous cells under conditions allowing the formation of hybridomas; (2) the detection and isolation of those of the said hybridomas which secrete monoclonal antibodies capable of inducing apoptosis in various tumor lines.

Claim 11 (withdrawn) ~~Use of an antibody according to one of claims 1 to 4, as diagnostic reagent.~~ A method of identifying G3BP protein, the method comprising contacting the antibody of claim 1 with a sample.

Claim 12 (canceled)

Claim 13 (previously presented) Monoclonal antibody according to claim 3, capable of recognizing an epitope between amino acids 22 to 55 SEQ ID NO:1.

Claim 14 (previously presented) Monoclonal antibody according to claim 13, capable of recognizing an epitope between amino acids 22 to 34 SEQ ID NO:1.

Respectfully submitted,



Joel B. German, Reg. No. 48,676  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone: 908-231-3444  
Telefax: 908-231-2626

Docket No. ST98017 US PCT